Skip to content
Search

Latest Stories

Pharmacies losing thousands of pounds monthly on NHS prescriptions - NPA analysis reveals

Pharmacies losing thousands of pounds monthly on NHS prescriptions - NPA analysis reveals

NHS funding falls way short of the price local pharmacies have to pay for many common medicines

The National Pharmacy Association (NPA) has raised the alarm that many community pharmacies are facing losses on NHS prescriptions due to the “broken” funding system.

An analysis of prescription drug prices by the NPA revealed that pharmacies are being underpaid by the NHS by up to £75 a pack for common medicines, resulting in losses of thousands of pounds each month.


The analysis report released today (16 October) shows the government reimburses £18.06 for a 56-tablet pack of Amantadine, a drug used to treat Parkinson’s symptoms.

However, the market price of the drug is £94.05 per pack, leading to a loss of £75.99 per 56-tablet pack for pharmacies—amounting to a shortfall of over £1 per tablet.

In some instances, NHS funding covers only one-fifth of the cost that pharmacies have to pay for medicines, according to new figures from the NPA.

A survey of small independent community pharmacies also found that 85 per cent often make a net loss on NHS prescribing.

Paul Rees, CEO of the NPA said: “It is nothing short of a national scandal that pharmacies have to dig deep into their own pockets just to cover the cost of basic medicines that they dispense to patients in need of treatment. No other health professional would be asked to subsidise a key NHS service.”

He stated that the funding system for medicines, which millions of patients rely on, is “utterly broken.”

Furthermore, Rees stated that the government's ambitions to expand the role of pharmacies, which they share, “cannot happen whilst they are being forced to closing at record numbers by chronic underfunding.”

“The government must step in now to halt pharmacy closures, fix the broken funding system and deliver a new deal for pharmacies which will end the terrible toll of closures and cuts to services,” he added.

A national NHS Drug Tariff, funded by the Department of Health, is designed to cover the costs of medicines purchased by local pharmacies from suppliers.

However, an analysis by the NPA of the difference between wholesale medicine costs and NHS funding rates found that government funding falls way short of the price local pharmacies have to pay for many common medicines.

A snapshot of prices carried out on 7 October also found that:

Pharmacies are paid £1.72 to dispense a pack of Escitalopram, a common anti-depressant, but it costs them £9.08 to buy from suppliers – more than five times the amount they are reimbursed by the government.  A pharmacy would lose £7.59 per pack they dispense to a patient.

  •  Pharmacies are paid £3.16 to dispense Lorazepam, an anti-anxiety medication. However, it costs them £10.75 to buy in from a supplier, around 3.5 times more than this. A pharmacy would lose £7.59 per pack they dispense to a patient.
  •  Etoricoxib, an anti-inflammatory drug to treat conditions such as rheumatoid arthritis, costs pharmacies £19.47 to buy from their supplier per pack. However, they receive £6.75 from the NHS to dispense the medication, a third of the cost. A pharmacy would lose £12.72 per pack they dispense to a patient.

An NPA survey conducted earlier this year showed that many existing pharmacies have been compelled to take drastic measures to stay open, with 64 per cent of independent pharmacy owners stating that they have borrowed money from family and friends or used their savings due to financial pressures.

The association, which represents independent community pharmacies in the UK, highlighted that chronic underfunding was placing intolerable financial pressure on pharmacies, leading to the closure of more than 1,500 in the past decade.

NHS funding accounts for 90 per cent of an average community pharmacy’s income, but it has fallen by 40 per cent real terms cuts since 2017, the NPA stated.

Recently, the NPA launched its first-ever ballot of its members in over 100 years, asking whether they should implement collective 'work to rule' measures if their funding situation does not improve.

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less